Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Saved in:
Bibliographic Details
Published in:Ophthalmology and Therapy
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1868552781382549504
collection WordPress RSS
FRELIP Feed Integration
container_title Ophthalmology and Therapy
description
discipline_display Ophthalmology and Optometry
discipline_facet Ophthalmology and Optometry
format Online Article
RSS Article
genre Journal Article
id rss_article:60980
institution FRELIP
journal_source_facet Ophthalmology and Therapy
last_indexed 2026-06-20T21:26:07.255Z
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
Ophthalmology and Optometry
General
Ophthalmology and Optometry
sub_discipline_display General
sub_discipline_facet General
subject_display Ophthalmology and Optometry
General
Ophthalmology and Optometry
subject_facet Ophthalmology and Optometry
General
Ophthalmology and Optometry
title Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_alt Resumen de investigación: beneficio económico de aflibercept 8 mg frente a faricimab para la degeneración macular neovascular asociada a la edad o el edema macular diabético en EE. UU.
Résumé de recherche : bénéfice économique de l'aflibercept 8 mg par rapport au faricimab pour la dégénérescence maculaire liée à l'âge néovasculaire ou l'œdème maculaire diabétique aux États-Unis
Resumo da Pesquisa: Benefício Econômico de Aflibercept 8 mg Versus Faricimab para Degeneração Macular Relacionada à Idade Neovascular ou Edema Macular Diabético nos EUA
title_auth Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_es_txt Resumen de investigación: beneficio económico de aflibercept 8 mg frente a faricimab para la degeneración macular neovascular asociada a la edad o el edema macular diabético en EE. UU.
title_fr_txt Résumé de recherche : bénéfice économique de l'aflibercept 8 mg par rapport au faricimab pour la dégénérescence maculaire liée à l'âge néovasculaire ou l'œdème maculaire diabétique aux États-Unis
title_full Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_fullStr Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_full_unstemmed Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_pt_txt Resumo da Pesquisa: Benefício Econômico de Aflibercept 8 mg Versus Faricimab para Degeneração Macular Relacionada à Idade Neovascular ou Edema Macular Diabético nos EUA
title_short Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
title_sort summary of research: economic benefit of aflibercept 8 mg versus faricimab for neovascular age-related macular degeneration or diabetic macular edema in the us
topic Ophthalmology and Optometry
General
Ophthalmology and Optometry
url https://link.springer.com/article/10.1007/s40123-026-01398-x